$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 同源康医药公布2026年中期业绩，研发成本为9494.3万元，同比增长7%;行政开支6255.4万元，同比增长61.3%;母公司拥有人应占亏损2489.7万元，同比收窄77.81%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":598021697139712,"tweetId":"598021697139712","gmtCreate":1787019554424,"gmtModify":1787019556654,"author":{"id":156361281180936,"idStr":"156361281180936","authorId":156361281180936,"authorIdStr":"156361281180936","name":"老油条的原则","avatar":"https://static.tigerbbs.com/504d0a0773c54de999742532a85f54b9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","name":"实盘交易者","description":"完成一笔实盘交易","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","name":"明星虎友","description":"加入老虎社区2000天","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康医药公布2026年中期业绩，研发成本为9494.3万元，同比增长7%;行政开支6255.4万元，同比增长61.3%;母公司拥有人应占亏损2489.7万元，同比收窄77.81%</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康医药公布2026年中期业绩，研发成本为9494.3万元，同比增长7%;行政开支6255.4万元，同比增长61.3%;母公司拥有人应占亏损2489.7万元，同比收窄77.81%</p></body></html>","text":"$同源康医药-B(02410)$ 同源康医药公布2026年中期业绩，研发成本为9494.3万元，同比增长7%;行政开支6255.4万元，同比增长61.3%;母公司拥有人应占亏损2489.7万元，同比收窄77.81%","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/598021697139712","repostId":0,"isVote":1,"tweetType":1,"viewCount":254,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":160,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/598021697139712"}